NRx Pharmaceuticals Stock Scheduled to Reverse Split on Tuesday, April 2nd (NASDAQ:NRXP)

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) are scheduled to reverse split on the morning of Tuesday, April 2nd. The 1-10 reverse split was announced on Tuesday, April 2nd. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, April 2nd.

NRx Pharmaceuticals Stock Down 11.0 %

Shares of NRXP stock opened at $0.47 on Friday. NRx Pharmaceuticals has a fifty-two week low of $0.22 and a fifty-two week high of $1.20. The stock has a market capitalization of $43.62 million, a P/E ratio of -0.93 and a beta of 0.99. The stock has a 50-day simple moving average of $0.47 and a 200 day simple moving average of $0.38.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of NRx Pharmaceuticals by 31.6% during the third quarter. Vanguard Group Inc. now owns 1,440,265 shares of the company’s stock valued at $1,065,000 after purchasing an additional 345,552 shares during the last quarter. AdvisorShares Investments LLC purchased a new stake in NRx Pharmaceuticals in the 4th quarter worth about $296,000. BlackRock Inc. lifted its stake in NRx Pharmaceuticals by 1.9% in the 1st quarter. BlackRock Inc. now owns 525,493 shares of the company’s stock worth $1,287,000 after acquiring an additional 10,045 shares in the last quarter. Geode Capital Management LLC lifted its stake in NRx Pharmaceuticals by 18.1% in the 4th quarter. Geode Capital Management LLC now owns 378,667 shares of the company’s stock worth $420,000 after acquiring an additional 58,040 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in NRx Pharmaceuticals in the 2nd quarter worth about $178,000. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression.